Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Revolution Medicines (RVMD) announced 11 presentations at the upcoming 2025 AACR Annual Meeting in Chicago (April 25-30, 2025). The highlight will be the first clinical data presentation of zoldonrasib, their RAS(ON) G12D-selective inhibitor, in non-small cell lung cancer patients during a late-breaking oral session.
Key presentations include preliminary safety and antitumor activity data of zoldonrasib in KRAS G12D NSCLC patients, the discovery of RMC-5127 (a RAS(ON) G12V-selective inhibitor), and clinical activity data of daraxonrasib in RAS mutant NSCLC. Additional presentations will cover resistance mechanisms, combination therapies, and immune response in various cancer types including pancreatic and colorectal cancers.
Revolution Medicines (RVMD) ha annunciato 11 presentazioni al prossimo 2025 AACR Annual Meeting a Chicago (25-30 aprile 2025). Il punto culminante sarà la prima presentazione dei dati clinici di zoldonrasib, il loro inibitore selettivo RAS(ON) G12D, nei pazienti con carcinoma polmonare non a piccole cellule durante una sessione orale di grande rilevanza.
Le presentazioni chiave includono dati preliminari sulla sicurezza e sull'attività antitumorale di zoldonrasib nei pazienti con NSCLC KRAS G12D, la scoperta di RMC-5127 (un inibitore selettivo RAS(ON) G12V) e dati sull'attività clinica di daraxonrasib nei NSCLC con mutazione RAS. Ulteriori presentazioni tratteranno i meccanismi di resistenza, le terapie combinate e la risposta immunitaria in vari tipi di cancro, tra cui i tumori pancreatici e colorettali.
Revolution Medicines (RVMD) anunció 11 presentaciones en la próxima Reunión Anual AACR 2025 en Chicago (25-30 de abril de 2025). El punto culminante será la primera presentación de datos clínicos de zoldonrasib, su inhibidor selectivo RAS(ON) G12D, en pacientes con cáncer de pulmón no microcítico durante una sesión oral de última hora.
Las presentaciones clave incluirán datos preliminares de seguridad y actividad antitumoral de zoldonrasib en pacientes con NSCLC KRAS G12D, el descubrimiento de RMC-5127 (un inhibidor selectivo RAS(ON) G12V) y datos de actividad clínica de daraxonrasib en NSCLC mutante de RAS. Presentaciones adicionales cubrirán mecanismos de resistencia, terapias combinadas y respuesta inmune en varios tipos de cáncer, incluidos los cánceres de páncreas y colorrectal.
Revolution Medicines (RVMD)는 오는 2025 AACR 연례 회의에서 11개의 발표를 할 예정이라고 발표했습니다. (2025년 4월 25-30일, 시카고). 하이라이트는 비소세포 폐암 환자에서 zoldonrasib의 첫 번째 임상 데이터 발표로, RAS(ON) G12D 선택적 억제제입니다. 이 발표는 늦은-breaking 구두 세션에서 이루어질 것입니다.
주요 발표 내용에는 KRAS G12D NSCLC 환자에서 zoldonrasib의 초기 안전성 및 항종양 활성 데이터, RMC-5127(즉, RAS(ON) G12V 선택적 억제제)의 발견, RAS 변이 NSCLC에서 daraxonrasib의 임상 활성 데이터가 포함됩니다. 추가 발표에서는 저항 메커니즘, 병용 요법 및 췌장암 및 대장암을 포함한 다양한 암 유형에서의 면역 반응을 다룰 것입니다.
Revolution Medicines (RVMD) a annoncé 11 présentations lors de la prochaine Réunion Annuelle AACR 2025 à Chicago (25-30 avril 2025). Le point culminant sera la première présentation des données cliniques de zoldonrasib, leur inhibiteur sélectif RAS(ON) G12D, chez des patients atteints de cancer du poumon non à petites cellules lors d'une session orale de dernière minute.
Les présentations clés incluent des données préliminaires sur la sécurité et l'activité antitumorale de zoldonrasib chez les patients NSCLC KRAS G12D, la découverte de RMC-5127 (un inhibiteur sélectif RAS(ON) G12V) et des données sur l'activité clinique de daraxonrasib dans le NSCLC mutant RAS. Des présentations supplémentaires aborderont les mécanismes de résistance, les thérapies combinées et la réponse immunitaire dans divers types de cancer, y compris les cancers du pancréas et colorectal.
Revolution Medicines (RVMD) hat 11 Präsentationen auf dem bevorstehenden 2025 AACR Annual Meeting in Chicago (25.-30. April 2025) angekündigt. Das Highlight wird die erste Präsentation klinischer Daten zu zoldonrasib, ihrem RAS(ON) G12D-selektiven Inhibitor, bei Patienten mit nicht-kleinzelligem Lungenkrebs während einer späten mündlichen Sitzung sein.
Wichtige Präsentationen umfassen vorläufige Sicherheits- und Antitumoraktivitätsdaten von zoldonrasib bei KRAS G12D NSCLC-Patienten, die Entdeckung von RMC-5127 (einem RAS(ON) G12V-selektiven Inhibitor) und klinische Aktivitätsdaten von daraxonrasib bei RAS-mutiertem NSCLC. Weitere Präsentationen werden Widerstandsmechanismen, Kombinationstherapien und Immunantworten bei verschiedenen Krebsarten, einschließlich Pankreas- und Kolorektalkrebs, behandeln.
- First clinical data reveal of zoldonrasib in NSCLC patients at a prestigious late-breaking session
- Broad pipeline demonstration with multiple drug candidates (zoldonrasib, RMC-5127, daraxonrasib, RMC-7977)
- Strong scientific presence with 11 presentations at major cancer conference
- None.
Insights
Revolution Medicines' upcoming presentation of first clinical data for zoldonrasib in non-small cell lung cancer represents a significant scientific milestone, though investor impact remains contingent on the actual efficacy and safety results. Zoldonrasib targets the KRAS G12D mutation, which has historically been challenging to drug and represents a substantial unmet need in cancer treatment.
The company's comprehensive approach to targeting RAS-driven cancers is evident from their 11 presentations, showcasing both mutation-selective inhibitors (zoldonrasib for G12D, RMC-5127 for G12V) and multi-selective inhibitors (daraxonrasib). This multi-pronged strategy provides multiple opportunities to address various RAS mutations that drive different cancer types.
Particularly noteworthy are the presentations examining resistance mechanisms and combination approaches with immunotherapy, indicating the company is strategically planning for potential challenges in treatment durability. The collaborations with prestigious cancer centers (Memorial Sloan Kettering, Dana-Farber) lend scientific credibility to their research program.
While this announcement establishes a clear catalyst timeline for investors, it's important to recognize that the actual impact will depend entirely on the quality of the data presented. This announcement itself doesn't change the fundamental outlook until we see the clinical results at the end of April.
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations will be featured at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, held from April 25 – 30, 2025.
The first clinical data in non-small cell lung cancer from the Phase 1 study of zoldonrasib, a RAS(ON) G12D-selective inhibitor, will be featured in a late breaking oral presentation.
Details of the abstracts are listed below:
Revolution Medicines Oral Presentations:
| Title: | Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a Phase 1 study in advanced solid tumors |
| Presenter: | Kathryn Arbour, M.D., Memorial Sloan Kettering Cancer Center |
| Abstract Number: | CT019 |
| Session: | New Frontiers in Precision Oncology |
| Date/Time: | April 27; 5:00 p.m. – 5:15 p.m. CST |
| Title: | Discovery of RMC-5127, an oral, RAS(ON) G12V-selective, noncovalent, tri-complex inhibitor |
| Presenter: | Anne Edwards, Ph.D. |
| Abstract Number: | ND06 |
| Session: | New Drugs on the Horizon: Part 2 |
| Date/Time: | April 27; 3:25 p.m. – 3:40 p.m. CST |
Revolution Medicines Poster Presentations:
| Title: | Early reduction in circulating tumor DNA (ctDNA) is associated with clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC) |
| Presenter: | Jia Luo, M.D., Dana-Farber Cancer Institute |
| Abstract Number: | LB218 |
| Session: | Late-Breaking Research: Clinical Research 1 |
| Date/Time: | April 28; 2:00 p.m. – 5:00 p.m. CST |
| Title: | Mechanisms of resistance to the RAS(ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC and potential resolution with RAS(ON) combination therapies |
| Presenter: | Mallika Singh, Ph.D. |
| Abstract Number: | LB281 |
| Session: | Late-Breaking Research: Experimental and Molecular Therapeutics 3 |
| Date/Time: | April 29; 9:00 a.m. – 12:00 p.m. CST |
| Title: | Combination of RAS(ON) mutant-selective and multi-selective inhibitors sensitizes immune-refractory, RAS-driven preclinical models to immunotherapy |
| Presenter: | Mariela Moreno Ayala, Ph.D. |
| Abstract Number: | 6046 |
| Session: | Adaptive Immunity in Tumors / Oncogenic Pathway-Mediated Regulation of Inflammation and Tumor Immunity |
| Date/Time: | April 29; 2:00 p.m. – 5:00 p.m. CST |
Collaborator Presentations
| Title: | Distinct regulation of Cyclin D mediates heterogenous response to RAS inhibition in colorectal cancer models |
| Presenter: | Philip Choi, M.D., Ph.D., Memorial Sloan Kettering Cancer Center |
| Abstract Number: | LB293 |
| Session: | Late-Breaking Research: Experimental and Molecular Therapeutics 3 |
| Date/Time: | April 29; 9:00 a.m. – 12:00 p.m. CST |
| Title: | Combining RAS(ON) G12C-selective and RAS(ON) multi-selective inhibitors overcomes sotorasib resistance driven by KRAS G12C amplification or NRAS G13R mutation |
| Presenter: | Hitendra Singh Solanki, Ph.D., Moffitt Cancer Center |
| Abstract Number: | 5512 |
| Session: | Drug Resistance in Molecular Targeted Therapies 3 |
| Date/Time: | April 29; 2:00 p.m. – 5:00 p.m. CST |
| Title: | A RAS(ON) multi-selective inhibitor combination therapy triggers long-term tumor control through senescence-associated tumor-immune equilibrium in preclinical models of PDAC |
| Presenter: | Caroline Broderick, Ph.D., Memorial Sloan Kettering Cancer Center |
| Abstract Number: | 5336 |
| Session: | CDK Inhibitors |
| Date/Time: | April 29; 2:00 p.m. – 5:00 p.m. CST |
| Title: | Preclinical evaluation of RMC-7977, a multi-selective RAS(ON) inhibitor, as a therapeutic strategy for KRAS-mutant cholangiocarcinoma |
| Presenter: | Jingjing Jiang, Ph.D. |
| Abstract Number: | 5691 |
| Session: | Oncogenes, Tumor Suppressor Genes, and Gene Products as Targets for Therapy 2 |
| Date/Time: | April 29; 2:00 p.m. – 5:00 p.m. CST |
| Title: | Mechanisms of resistance to RAS-GTP inhibition in pancreatic cancer |
| Presenter: | Joshua H. Choe, Dana-Farber Cancer Institute |
| Abstract Number: | 5507 |
| Session: | Drug Resistance in Molecular Targeted Therapies 3 |
| Date/Time: | April 29; 2:00 p.m. – 5:00 p.m. CST |
| Title: | T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of PDAC |
| Presenter: | Margo I. Orlen, Penn Medicine |
| Abstract Number: | 6405 |
| Session: | Checkpoints and Modulators of Tumor Microenvironment |
| Date/Time: | April 29; 3:25 p.m. – 3:40 p.m. CST |
About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.
Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com
FAQ
What is the key clinical data being presented for RVMD's zoldonrasib at AACR 2025?
How many presentations will Revolution Medicines (RVMD) deliver at AACR 2025?
What are the key drug candidates RVMD is presenting data on at AACR 2025?
What types of cancers are being targeted in RVMD's AACR 2025 presentations?
